Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Fleming

Showing results (651-660 of 760) with videos related to

Pageof 76
Sort By:
Cancer Gene Therapy|June 20, 2015
Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgeryS Yano, Y Hiroshima, A Maawy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2021
Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic CancerAslamuzzaman Kazi, Liwei Chen, Shengyan Xiang, et al.
Annals of Surgery|December 19, 2019
The Impact of Socioeconomic Deprivation on Clinical Outcomes for Pancreatic Adenocarcinoma at a High-volume Cancer Center: A Retrospective Cohort AnalysisBenjamin D Powers, William Fulp, Amina Dhahri, et al.
Molecular Carcinogenesis|April 12, 2023
Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancerDiego Alem, Xinrui Yang, Francisca Beato, et al.
Annals of Surgical Oncology|September 10, 2015
The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative TherapyChristina L Roland, Matthew H G Katz, Ching-Wei D Tzeng, et al.
Annals of Surgical Oncology|October 30, 2014
Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancerChristina L Roland, Anthony D Yang, Matthew H G Katz, et al.
Surgery Open Science|March 7, 2023
The impact of age and comorbidity on localized pancreatic cancer outcomes: A US retrospective cohort analysis with implications for surgical centralizationBenjamin D Powers, Kelvin Allenson, Jennifer A Perone, et al.
Annals of Surgical Oncology|February 8, 2008
Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancerRosa F Hwang, Huamin Wang, Axbal Lara, et al.
The American Journal of Surgical Pathology|February 4, 2012
Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinomaDeyali Chatterjee, Matthew H Katz, Asif Rashid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2011
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progressionChristopher H Crane, Gauri R Varadhachary, John S Yordy, et al.
Pageof 76

Showing results (651-660 of 760) with videos related to

Sort By:
Pageof 76
Cancer Gene Therapy|June 20, 2015
Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgeryS Yano, Y Hiroshima, A Maawy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2021
Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic CancerAslamuzzaman Kazi, Liwei Chen, Shengyan Xiang, et al.
Annals of Surgery|December 19, 2019
The Impact of Socioeconomic Deprivation on Clinical Outcomes for Pancreatic Adenocarcinoma at a High-volume Cancer Center: A Retrospective Cohort AnalysisBenjamin D Powers, William Fulp, Amina Dhahri, et al.
Molecular Carcinogenesis|April 12, 2023
Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancerDiego Alem, Xinrui Yang, Francisca Beato, et al.
Annals of Surgical Oncology|September 10, 2015
The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative TherapyChristina L Roland, Matthew H G Katz, Ching-Wei D Tzeng, et al.
Annals of Surgical Oncology|October 30, 2014
Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancerChristina L Roland, Anthony D Yang, Matthew H G Katz, et al.
Surgery Open Science|March 7, 2023
The impact of age and comorbidity on localized pancreatic cancer outcomes: A US retrospective cohort analysis with implications for surgical centralizationBenjamin D Powers, Kelvin Allenson, Jennifer A Perone, et al.
Annals of Surgical Oncology|February 8, 2008
Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancerRosa F Hwang, Huamin Wang, Axbal Lara, et al.
The American Journal of Surgical Pathology|February 4, 2012
Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinomaDeyali Chatterjee, Matthew H Katz, Asif Rashid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2011
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progressionChristopher H Crane, Gauri R Varadhachary, John S Yordy, et al.
Pageof 76